401 related articles for article (PubMed ID: 35294956)
21. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
Froyen G; Geerdens E; Berden S; Cruys B; Maes B
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
[TBL] [Abstract][Full Text] [Related]
24. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
[TBL] [Abstract][Full Text] [Related]
25. An approach for improvement of the accuracy of cancer gene panel testing.
Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
[TBL] [Abstract][Full Text] [Related]
26. Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.
Lin DI; Huang RSP; Ladas I; Keller RB; Patel NR; Lakis S; Decker B; Janovitz T; Mata DA; Ross JS; Vergilio JA; Elvin JA; Herbst RS; Mack PC; Killian JK
Front Oncol; 2024; 14():1328512. PubMed ID: 38444675
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R
PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
[TBL] [Abstract][Full Text] [Related]
29. Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test.
Ferguson S; Sriram S; Wallace JK; Lee J; Kim JA; Lee Y; Oh BB; Lee WC; Lee S; Connolly-Strong E
Cancer Invest; 2024 May; 42(5):390-399. PubMed ID: 38773925
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
[TBL] [Abstract][Full Text] [Related]
31. [Crosstalk of Cancer Genomic Test and Cancer Immune Therapy].
Nishihara H
Gan To Kagaku Ryoho; 2022 Mar; 49(3):248-254. PubMed ID: 35299175
[TBL] [Abstract][Full Text] [Related]
32. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra
White T; Szelinger S; LoBello J; King A; Aldrich J; Garinger N; Halbert M; Richholt RF; Mastrian SD; Babb C; Ozols AA; Goodman LJ; Basu GD; Royce T
Oncotarget; 2021 Apr; 12(8):726-739. PubMed ID: 33889297
[TBL] [Abstract][Full Text] [Related]
33. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
[TBL] [Abstract][Full Text] [Related]
34. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D
J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
Ido M; Fujii K; Mishima H; Kubo A; Saito M; Banno H; Ito Y; Goto M; Ando T; Mouri Y; Kousaka J; Imai T; Nakano S
BMC Cancer; 2024 Jan; 24(1):85. PubMed ID: 38229073
[TBL] [Abstract][Full Text] [Related]
36. Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.
Paasinen-Sohns A; Koelzer VH; Frank A; Schafroth J; Gisler A; Sachs M; Graber A; Rothschild SI; Wicki A; Cathomas G; Mertz KD
Neoplasia; 2017 Mar; 19(3):196-206. PubMed ID: 28161563
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
38. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
[TBL] [Abstract][Full Text] [Related]
39. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
40. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
